Surya Bhatt, MD, associate professor of medicine at University of Alabama at Birmingham, talks about a new trial in which dupilumab was used in patients with chronic obstructive pulmonary disease (COPD) with frequent exacerbations and type 2 inflammation.
Patients with chronic obstructive pulmonary disease (COPD) who also exhibit type 2 inflammation and exacerbations were sought for a trial using dupilumab, said Surya Bhatt, MD, associate professor of medicine at University of Alabama at Birmingham. The study, “Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was presented recently at the American Thoracic Society (ATS) International Conference.
Transcript
Dupilumab is already approved for other indications—can you summarize how it works and why it is being tested for COPD?
Dupilumab is a humanized monoclonal antibody that targets the [interleukin] IL-4 alpha receptor, which is integral to both IL-4 as well as IL-13, and that way it blocks both IL-4 and IL-13 which are very critical for type 2 inflammation in patients with COPD. It's been increasingly recognized that about 20 to 40% of patients with COPD have type 2 inflammation, and they're more likely to suffer from repeated exacerbations. That is the reason why we're targeting patients with COPD with frequent exacerbations and type 2 inflammation with dupilumab.
Who was the patient population in the BOREAS trial of dupilumab and what type of COPD did they have?
BOREAS targeted patients with COPD with type 2 inflammation, and the main inclusion criterion were patients who were current or former smokers with at least a 10 pack/year smoking history and at high exacerbation risk, which was defined as at least 2 moderate exacerbations or 1 severe exacerbation in the previous year. And, they had to have an eosinophil count of at least 300 cells per microliter in the blood to be eligible.
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More